458 related articles for article (PubMed ID: 8819523)
1. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
2. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.
Turner CR; Cohan VL; Cheng JB; Showell HJ; Pazoles CJ; Watson JW
J Pharmacol Exp Ther; 1996 Sep; 278(3):1349-55. PubMed ID: 8819522
[TBL] [Abstract][Full Text] [Related]
3. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
5. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
Cheng JB; Watson JW; Pazoles CJ; Eskra JD; Griffiths RJ; Cohan VL; Turner CR; Showell HJ; Pettipher ER
J Pharmacol Exp Ther; 1997 Feb; 280(2):621-6. PubMed ID: 9023272
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
7. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
8. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.
Tenor H; Hatzelmann A; Church MK; Schudt C; Shute JK
Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438
[TBL] [Abstract][Full Text] [Related]
9. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
10. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
11. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
12. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one].
Boswell-Smith V; Spina D; Oxford AW; Comer MB; Seeds EA; Page CP
J Pharmacol Exp Ther; 2006 Aug; 318(2):840-8. PubMed ID: 16682455
[TBL] [Abstract][Full Text] [Related]
14. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
16. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
17. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor.
Wright KF; Turner CR; Jayasinghe-Beck R; Cohen VL; Cheng JB; Watson JW
Can J Physiol Pharmacol; 1997 Aug; 75(8):1001-8. PubMed ID: 9360015
[TBL] [Abstract][Full Text] [Related]
18. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
20. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
